Pharma Sector

The revised scheme removes the minimum sales threshold, lowers investment requirements and offers higher incentives for critical components and advanced medical devices

Morepen's first US prescription generic launch expands its presence beyond API supplies into finished-dosage medicines and distribution.

Biocon's Q2FY27 net profit fell 52 per cent to ₹41 crore as delayed shipments worth $20 million hit margins, while revenue rose 2 per cent to ₹4,389 crore.

Emcure Pharmaceuticals reports 24.2 per cent revenue growth in Q2FY27, led by strong international sales, while domestic business expands 12 per cent and net profit rises 33.7 per cent

The Union Health Ministry has proposed expanding the network of authorised import gateways for drugs, medical devices and cosmetics by adding several inland container depots, a special economic zone and an international airport to facilitate faster clearance and improve supply chain efficiency. The proposed amendment to Rule 43A of the Drugs Rules, 1945, seeks to include additional entry points in Haryana, Uttar Pradesh, Gujarat, Telangana and Karnataka, according to a gazette notification issued by the ministry. The proposed locations include Inland Container Depots (ICDs) at Sonipat, Piyala and Harsaru in Haryana; Dadri in Uttar Pradesh; Gandhidham/Mundra in Gujarat; Sanath Nagar and Thimmapur in Hyderabad; and Whitefield in Bengaluru. The ministry has also proposed including the Bommasandra Special Economic Zone (SEZ) in Karnataka and Noida International Airport in Uttar Pradesh for the import of drugs by air. Rule 43A specifies the authorised ports, airports, railway stations,

Analysts remain positive on Sun Pharma despite slower US and speciality growth in Q2FY27, supported by strong domestic sales, though near-term earnings estimates have been cut.

The drugmaker plans to deploy ₹500 crore for another acquisition within 12 months as it targets 25 per cent annual growth in its API business over the next five years

Modernising pharma through enterprise resource planning (ERP) transformation replaces vulnerable legacy systems with a single source of truth, ensuring uninterrupted manufacturing continuity, according to experts. "This digital evolution gives life sciences companies the agility and data integrity needed to seamlessly meet strict regulatory requirements," Mandar Ghatnekar, Chief Technology Officer, Biocon, said while addressing the 15th edition of the Pharma IT Summit Mumbai 2026 organised by Exito Media Concepts earlier in the week. Speakers from top pharmaceutical companies, who attended the summit, also advocated for the need for human review of GenAI outputs, particularly in a good practice (GxP) environment. "In a highly regulated industry like pharmaceuticals, successful AI adoption requires a strong foundation of people, process, technology and governance, balancing innovation with regulatory compliance and operational excellence. "The future of AI will be defined not by how

India's pharmaceutical exports rose 4.9 per cent to $16.14 billion in H1FY27, driven by growth in Europe, ASEAN and Latin America, even as shipments to the US moderated.

India's pharma and healthcare sector recorded 87 deals worth $4.3 billion in Q3 2026, as private equity activity surged and public market fundraising gained momentum.

Major innovator brands see no price reductions despite cuts of up to 93 per cent for some cancer medicines; patient groups say PAP exclusions and data gaps have diluted relief

The company attributed the decline primarily to lower lenalidomide sales in North America. The base business, excluding lenalidomide in North America, continued to deliver double-digit growth

The three-member committee will assess the effectiveness of the UCPMP, examine enforcement mechanisms and recommend measures to curb unethical pharmaceutical marketing practices

Torrent Pharma's Q2FY27 net profit declined 9.6 per cent to ₹534 crore despite a 50.8 per cent rise in revenue, as higher finance costs and depreciation weighed on earnings

The addressable ​market could grow at an annual rate of 15% through 2035, JP Morgan ‌analysts led by Yang Huang said in a note on Friday, given the countries' large diabetes and obesity burdens

Next phase of growth hinges on biologics, peptides, and drug-device combinations, say industry executives

Sun Pharma has accepted bids worth ₹7,816 crore for two bond tranches maturing in five years and one day, offering annual coupons of 8.05% and 8.20%, merchant bankers said.

Weak demand, AI-led growth concerns and US export headwinds weigh on defensive stocks, while valuation moderation signals potential opportunities

Generic brands now account for about 74% of monthly units as lower-priced products expand access, while doctors say the initial rush around the drug is cooling

The Supreme Court has directed the Centre to constitute a committee to examine statutory regulations on pharmaceutical marketing, including gifts and incentives offered to doctors